Regenerex Pharma (RGPX) Income from Continuing Operations (2010 - 2025)

Regenerex Pharma (RGPX) has 13 years of Income from Continuing Operations data on file, last reported at 790659.0 in Q3 2025.

• Income from Continuing Operations for Q3 2025 came in at 790659.0, down 50.73% year-over-year; the trailing twelve-month figure through Sep 2025 was 3092068.0 (down 117.86% YoY), and the FY2025 annual result was 2143427.0, up 39.56% from the prior year.
• Income from Continuing Operations slipped to 790659.0 in Q3 2025 per RGPX's latest filing, from 657266.0 in the prior quarter.
• Over five years, Income from Continuing Operations peaked at 24430.0 in Q2 2021 and troughed at 2805724.0 in Q3 2023.
• A 5-year average of 438473.94 and a median of 219141.5 in 2023 frame the typical range for Income from Continuing Operations.
• The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations tumbled 7261.98% in 2023, then surged 81.3% in 2024.
• A 5-year view of Income from Continuing Operations shows it stood at 76523.0 in 2021, then jumped by 39.44% to 46343.0 in 2022, then plunged by 460.18% to 259603.0 in 2023, then plunged by 30.4% to 338526.0 in 2024, then slumped by 133.56% to 790659.0 in 2025.
• Business Quant data shows RGPX's Income from Continuing Operations at 790659.0 in Q3 2025, 657266.0 in Q2 2025, and 1305617.0 in Q1 2025.